Person: KARALI, YASİN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARALI
First Name
YASİN
Name
19 results
Search Results
Now showing 1 - 10 of 19
Publication Challenges in investigating patients with isolated decreased serum IgM: The SIMcal study(Wiley, 2019-06-01) Janssen, Lisanne M. A.; van Hout, Roeland W. N. M.; de Vries, Esther; Pignata, Claudio; Cirillo, Emilia; Arkwright, Peter D.; Lougaris, Vassilos; Buckland, Matthew; Garcia-Prat, Marina; Soler-Palacin, Pere; Ouederni, Monia; Kralickova, Pavlina; Abolhassani, Hassan; Hammerstroem, Lennart; Aghamohammadi, Asghar; Santos-Perez, Juan L.; Sobh, Ali; ten Bosch, Jutte van de Werff; Henriet, Stefanie; Kılıç, Sara S.; Karalı, Yasin; Ignacio Gonzalez-Granado, Luis; Sediva, Anna; SIMcal Consortium; KILIÇ GÜLTEKİN, SARA ŞEBNEM; KARALI, YASİN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk İmmunoloji Anabilim Dalı.; AAH-1658-2021; FFS-1974-2022The clinical consequences of isolated decreased serum immunoglobulin (Ig)M are not sufficiently known. Therefore, it is difficult to determine the clinical policy following such a finding. Only few reported IgM-deficient patients fulfil the European Society for Immunodeficiencies (ESID) diagnostic criteria for selective IgM deficiency (true sIgMdef), or their diagnosis is uncertain due to insufficient laboratory data (possible sIgMdef). Decreased serum IgM is often incidentally found in asymptomatic adults. The objective of our study was to further characterize true sIgMdef and to compare the European data collected through the ESID Registry community (tertiary centres) to our previously published Dutch cohort (secondary centre). Fifteen centres (12 countries) participated with 98 patients. Patients were excluded if serum IgM was only determined once (n = 14), had normalized (n = 8), or if they also had other immunological abnormalities (n = 15). Ten patients (5 adults) completely fulfilled the ESID criteria for true sIgMdef. Age-matched cut-off values varied widely between centres; when using the ESID diagnostic protocol reference values, only six patients (five adults) had true sIgMdef. Because of these small numbers, further analyses were performed in patients with true or possible sIgMdef (13 adults, 48 children). Respiratory infections were commonly reported at presentation (adults 54%, children 60%). Symptomatic adults had lower serum IgM levels (mean 0.27 g/L, 95% CI 0.22-0.31) than those without symptoms (mean 0.33 g/L, 95% CI 0.30-0.36; P = 0.02). To be able to explore the clinical consequences of true sIgMdef, we should fully analyse and accurately describe those patients in whom a decreased serum IgM is found.Publication Knowledge levels of mothers of asthmatic children about asthma(Dr Behcet Uz Cocuk Hastaliklari Ve Cerrahisi, 2020-01-01) Çekiç, Şükrü; ÇEKİÇ, ŞÜKRÜ; Canıtez, Yakup; CANITEZ, YAKUP; Küçüker, Hakan; KÜÇÜKER, HAKAN; Karali, Yasin; KARALI, YASİN; Çiçek, Fatih; ÇİÇEK, FATİH; Sapan, Nihat; SAPAN, NİHAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; 0000-0002-9574-1842; L-1933-2017Objective: Compliance of the family with asthma treatment is one of the main factors determining the success of treatment. This study aimed to investigate the knowledge level of the mothers with asthmatic children about symptoms, diagnosis and treatment of asthmaMethod: A questionnaire consisting of 42 questions was used in the study. The questionnaire was composed of questions prepared by us and adapted from a validated asthma knowledge level questionnaire. Each correct answer was evaluated as 2.38 points. Those receiving 67.7 points above were considered sufficient.Results: 323 mothers of children with asthma were included in the study. None of the mothers answered all the questions correctly among. The total mean score of the mothers was 57.8 +/- 11.9 (median: 58.5, minimum: 26.8, maximum: 87.8). The median scores of the mothers who graduated from university (median: 65.9, minimum: 36.6, maximum: 85.4) was higher than those who graduated from primary school (median: 53.7, minimum: 29.3, maximum: 87.8), middle school (median: 58.5, minimum: 29.3, maximum: 78) and high school (median: 61, minimum: 26.8, maximum: 80.5) (p<0.001, p<0.001 and p=0.003). The median score of working mothers (median: 65.9, minimum: 34.1, maximum: 87.8) was higher than those who were housewives (median: 56.1, minimum: 26.8, maximum: 87.8) (p<0.001). The median score of mothers who breastfed for more than six months (median: 61, minimum: 29.3, maximum: 87.8) was higher compared to those who breastfed less than six months (median: 56.1, minimum: 26.8, maximum: 85.4) (p=0.005).Conclusion: Education levels of the mothers and being a working mother were significant factors affecting the level of asthma knowledge among mothers.Publication Cancer tendency in a patient with ZNF341 deficiency(Springer/Plenum Publishers, 2020-01-20) Çekiç, Şükrü; Hartberger, Julia Maria; Frey-Jakobs, Stefanie; Hüriyet, Hüzeyfe; Hortoğlu, Melika Bektaş; Neubauer, Johanna Charlotte; Karalı, Yasin; Abakay, Candan Demiröz; Saraydaroğlu, Özlem; Çavaş, Tolga; Grimbacher, Bodo; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; Huriyet, Huzeyfe; BEKTAŞ HORTOĞLU, MELİKA; KARALI, YASİN; DEMİRÖZ ABAKAY, CANDAN; SARAYDAROĞLU, ÖZLEM; ÇAVAŞ, TOLGA; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-9574-1842; 0000-0003-1620-1918; 0000-0002-6897-6806; 0000-0001-8571-2581; 0000-0002-5617-8313; L-1933-2017; JBJ-7521-2023; AAH-3855-2021; AAA-4154-2022; AAH-1658-2021; AAH-9701-2021; AAH-3508-2021; CVI-9578-2022; FFS-1974-2022Publication Three different faces of taci mutations(Wiley, 2020-04-08) Çekic, Şükrü; Çicek, Fatih; Karalı, Yasin; Görükmez, Orhan; Eren, Erdal; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; ÇİÇEK, FATİH; KARALI, YASİN; EREN, ERDAL; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik Alerji ve Klinik İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinolojisi Anabilim Dalı.; 0000-0002-9574-1842; 0000-0001-7348-7081; 0000-0002-1684-1053; 0000-0001-8571-2581; 0000-0002-1245-4232; AAH-1658-2021; JPK-3909-2023; JKI-5906-2023; L-1933-2017; FFS-1974-2022Publication Omalizumab treatment in childhood chronic urticaria(Wiley, 2018-08-01) Çekiç, Şükrü; Karali, Yasin; Canıtez, Yakup; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; CANITEZ, YAKUP; SAPAN, NİHAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatri ve Alerji Bölümü; 0000-0002-9574-1842; L-1933-2017; FFS-1974-2022; CJQ-2060-2022; FUI-8766-2022Publication Vedolizumab treatment in a patient with x-linked agammaglobulinemia, is it safe and efficient?(Türk Pediatri Dergisi, 2019-11-01) Çekiç, Şükrü; Özgür, Taner; Karalı, Yasin; Özkan, Tanju; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; ÖZGÜR, TANER; KARALI, YASİN; ÖZKAN, TANJU MUNEVVER; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik Gastroenteroloji Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0001-5740-9729; 0000-0001-8571-2581; AAG-8416-2021; AAG-8381-2021; AAH-1658-2021; L-1933-2017; FFS-1974-2022The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as children with another primary immunodeficiency (PID) diseases. A 4-year-old boy was admitted to our clinic with a history of recurrent respiratory tract infections. He was diagnosed with XLA based on extremely low immunoglobulins, very low level of B cells, genetic mutation of BTK gene, and family history. At the age of 8, he suffered from intermittent fever attacks, abdominal pain, weakness, oral aft, and weight loss. His clinical and laboratory features were consistent with inflammatory bowel disease. Histopathological examination of the biopsy material obtained from terminal ileum, colon and cecum showed Crohn's disease. Initially, he was treated with prednisolone and infliximab. Because of the lack of response, infliximab treatment was switched to adalimumab. Terminal ileum was resected to relieve obstruction complication. Although he had been treated with adalimumab, a significant improvement was not observed. Vedolizumab (Entyvio (TM)), a humanized monoclonal antibody alpha 4 beta 7 integrin-receptor antagonist, was commenced. After treatment with vedolizumab, his fever and abdominal pain attacks reduced, his total daily calorie intake increased and weight gain improved. He began to walk again and continued his school education properly. No side effects were observed in 18 months. This is the first immunocompromised child treated with vedolizumab. The symptoms of the patient receded and no side effect were seen during the treatment.Publication Vedolizumab treatment in patient with Xla, is it safe and efficient?(Wiley, 2018-08-01) Çekiç, Şükran; Özgür, Taner; Karalı, Yasin; Özkan, Tanju Başarır; Kılıç, S. S.; ÇEKİÇ, ŞÜKRÜ; ÖZGÜR, TANER; KARALI, YASİN; ÖZKAN, TANJU MUNEVVER; Kılıç, S. S.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Gastroenteroloji Bilim Dalı; 0000-0002-9574-1842; 0000-0001-8571-2581; AAG-8381-2021; AAH-1658-2021; GBO-8694-2022; FFS-1974-2022; IGX-1808-2023Publication Autoimmune and inflammatory diseases in primary immune deficiencies(Wiley, 2019-08-01) Çekiç, Şükrü; Karali, Yasin; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Uludağ Üniversitesi/Tıp Fakültesi/Pediatri-Alerji Bölümü; 0000-0002-9574-1842; 0000-0001-8571-2581; AAH-1658-2021; L-1933-2017; FFS-1974-2022Publication Two cases with homozygous TACI mutation; could TACI mutation be a cause of microcephaly and growth retardation?(Wiley, 2019-08-01) Kılıç, Sara Şebnem; Çiçek, Fatih; Çekiç, Şükrü; Karali, Yasin; KILIÇ GÜLTEKİN, SARA ŞEBNEM; ÇİÇEK, FATİH; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0001-8571-2581; 0000-0001-7348-7081; 0000-0002-9574-1842; AAH-1658-2021; JMD-8408-2023; GBO-8694-2022; FFS-1974-2022Publication Vedolizumab treatment in a patient with x-linked agammaglobulinemia, is it safe and efficient?(Turkish J Pediatrics, 2019-11-01) Kılıç, Sara Sebnem; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Çekiç, Sükrü; ÇEKİÇ, ŞÜKRÜ; Özgür, Taner; ÖZGÜR, TANER; Özkan, Tanju; ÖZKAN, TANJU MUNEVVER; Karali, Yasin; KARALI, YASİN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı.; 0000-0002-9574-1842; 0000-0001-5740-9729; 0000-0001-8571-2581; AAG-8416-2021; AAH-1658-2021; L-1933-2017; AAG-8381-2021The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as children with another primary immunodeficiency (PID) diseases. A 4-year-old boy was admitted to our clinic with a history of recurrent respiratory tract infections. He was diagnosed with XLA based on extremely low immunoglobulins, very low level of B cells, genetic mutation of BTK gene, and family history. At the age of 8, he suffered from intermittent fever attacks, abdominal pain, weakness, oral aft, and weight loss. His clinical and laboratory features were consistent with inflammatory bowel disease. Histopathological examination of the biopsy material obtained from terminal ileum, colon and cecum showed Crohn's disease. Initially, he was treated with prednisolone and infliximab. Because of the lack of response, infliximab treatment was switched to adalimumab. Terminal ileum was resected to relieve obstruction complication. Although he had been treated with adalimumab, a significant improvement was not observed. Vedolizumab (Entyvio (TM)), a humanized monoclonal antibody alpha 4 beta 7 integrin-receptor antagonist, was commenced. After treatment with vedolizumab, his fever and abdominal pain attacks reduced, his total daily calorie intake increased and weight gain improved. He began to walk again and continued his school education properly. No side effects were observed in 18 months. This is the first immunocompromised child treated with vedolizumab. The symptoms of the patient receded and no side effect were seen during the treatment.